Article | March 14, 2022

Outsourcing Process Development: Key Considerations For Biopharma Companies

Source: Cytiva
GettyImages-1201263001-lab-team

A wide range of new opportunities in global healthcare have been created by a record level of investments across the biopharma industry. "Venture-capital funding, initial public offerings, and secondary offerings by already-public companies led to $88 billion in new equity in 2020, with most going toward emerging biopharma companies," according to the Drug, Chemical & Associated Technologies Association, data from investment firm Jefferies Financial Group Inc.1 This will likely result in a flurry of collaborations with contract development and manufacturing organizations (CDMOs) to help fill expertise and resource gaps within these developing companies.

Whether you are just entering the field or responding to the influx of competition, you must know how to vet potential providers, especially for process development services. This critical step is a key factor in determining your drug program’s overall success.

A panel of experts with experienced and diverse perspectives discussed this topic during an online event titled Best Practices for Outsourcing Process Development, where four themes surfaced that may help drive the best outcomes with your process development service provider.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development